Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $2.8 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 18.03% year-over-year to $2.8 billion in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 18.03% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 15.5% from the prior year.
• Total Non-Current Liabilities declined to $2.8 billion in Q1 2026 per AMRX's latest filing, from $2.8 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $2.9 billion in Q1 2022 and bottomed at $2.3 billion in Q1 2025.
• The 5-year median for Total Non-Current Liabilities is $2.7 billion (2023), against an average of $2.7 billion.
• Across the five-year window, Total Non-Current Liabilities declined 12.44% in 2024 and grew 18.03% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.8 billion in 2022, then retreated by 9.62% to $2.6 billion in 2023, then declined by 5.79% to $2.4 billion in 2024, then advanced by 15.5% to $2.8 billion in 2025, then dropped by 0.66% to $2.8 billion in 2026.
• Per Business Quant, the three latest AMRX Total Non-Current Liabilities figures stand at $2.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025).